ProCE Banner Activity

CE / CME

Optimizing Multiple Myeloma Care: Expert Guidance for the Practicing Clinician

Watch this on-demand Webcast capturing a live CCO Webinar featuring an expert presentation on optimizing multiple myeloma care for practicing clinicians

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Registered Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Released: October 08, 2020

Expiration: October 07, 2021

No longer available for credit.

Share

Faculty

Sarah A. Holstein

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by USF Health in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Celgene

GlaxoSmithKline LLC

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Sanofi Genzyme Corp

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Manage disease-related and treatment-related symptoms in patients with multiple myeloma

Faculty Disclosure

Primary Author

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Sarah A. Holstein, MD, PhD, has disclosed that she has participated in advisory boards for Genentech and GlaxoSmithKline; has consulted for Celgene, Oncopeptides, and Sorrento; and has received grants or research support from Oncopeptides.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.0 contact hour (0.1 CEU). Universal program number is as follows: 0230-9999-20-030-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Disclosure of Unlabeled Use

USF Health OCPD staff have no relevant conflicts of interest to report.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 08, 2020, through October 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with multiple myeloma.